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Circular RNAs (circRNAs) constitute a family of tran-
scripts with unique structures and still largely un-
known functions. Their biogenesis, which proceeds
via a back-splicing reaction, is fairly well character-
ized, whereas their role in the modulation of physio-
logically relevant processes is still unclear. Here
we performed expression profiling of circRNAs
during in vitro differentiation of murine and human
myoblasts, and we identified conserved species
regulated in myogenesis and altered in Duchenne
muscular dystrophy. A high-content functional
genomic screen allowed the study of their func-
tional role in muscle differentiation. One of them,
circ-ZNF609, resulted in specifically controlling
myoblast proliferation. Circ-ZNF609 contains an
open reading frame spanning from the start codon,
in common with the linear transcript, and terminat-
ing at an in-frame STOP codon, created upon circu-
larization. Circ-ZNF609 is associated with heavy
polysomes, and it is translated into a protein in a
splicing-dependent and cap-independent manner,
providing an example of a protein-coding circRNA
in eukaryotes.
INTRODUCTION
RNA molecules lacking 50 and 30 ends and shaped as covalently
closed circular RNAs (circRNAs) were described decades ago in
a variety of model systems, but they were considered rare events
(Sanger et al., 1976; Capel et al., 1993). However, recent studies
report that these molecules are commonly produced by thou-
sands of genes (Salzman et al., 2012; Jeck et al., 2013;Memczak
et al., 2013) and are usually generated by the joining of a 50 splice
site with the 30 splice site of an upstream intron, in a so-called
back-splicing reaction (Hansen et al., 2011; Ashwal-Fluss et al.,22 Molecular Cell 66, 22–37, April 6, 2017 ª 2017 The Authors. Publi
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that circRNAexpression is oftenhighly conservedacross species
and particularly abundant in mammalian neuronal tissues (Ry-
bak-Wolf et al., 2015).Moreover, theDNA that encodes circRNAs
is more conserved than the DNA of flanking exons (Rybak-Wolf
et al., 2015). Very little is known about their mechanism of ac-
tion; some may be sponges for microRNAs (miRNAs), as shown
for CDR1as and SRY in vertebrate neuronal tissues (Memczak
et al., 2013; Hansen et al., 2013) and for circ-HIPK3 in human
cancers (Zheng et al., 2016). Nevertheless, genome-wide studies
have demonstrated that miRNA sponging activity cannot be
generally applied (Memczak et al., 2013; You et al., 2015; Jeck
and Sharpless, 2014), and other mechanisms have also been
proposed, such as acting as platforms for protein interaction
(Hentze and Preiss, 2013). This specifically pertains to circ-Mbl,
which competes for the splicing of its linear counterpart by bind-
ing to Mbl (Ashwal-Fluss et al., 2014), and to circ-Foxo3, which
blocks cell-cycle progression by interacting with Cdk (Du et al.,
2016). Emerging evidence also suggests a potential role of
circRNAs in different human diseases (Chen et al., 2016), with
data indicating tumor-promoting properties in in vivo models
(Guarnerio et al., 2016). Despite these data in favor of circRNAs’
relevant functional roles, their impact on biological processes is
still largely unexplored.
In this work, we have identified conserved circRNAs that are
regulated during murine and human muscle differentiation
and whose expression is altered in Duchenne muscular dystro-
phy (DMD) myoblasts. A dedicated knockdown strategy fol-
lowed by a high-content phenotypic screening identified
circRNAs’ participation in the control of myogenesis; circ-
ZNF609, selected on the basis of its ability to regulate myoblast
proliferation, provided an interesting example of translation
occurring on a circRNA.
RESULTS
CircRNAs Are Abundant, Conserved, and Highly
Expressed
Total RNA was collected from two replicates of human and
mouse (C2C12) myoblasts cultured in growth medium (GM) orshed by Elsevier Inc.
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Identification of CircRNAs in Mammalian Myoblast Differentiation
(A) Experimental and computational pipelines for the identification of circRNAs from human and mouse myoblasts (expressing MyoD and Myf5) and myotubes
(expressing Myosin Heavy Chain [MHC] and Muscle Creatin Kinase [CKM]). Blue, rRNA and genomic reads; blue-red, reads across linear splice junctions; red,
reads across back-splicing junctions.
(B) Number of detected linear and circular splicing events per sample with bona fide circRNAs passing selection filters (see the STAR Methods). Samples are
human primary and mouse C2C12 myoblasts (GM) and myotubes (DM) in two replicates (A and B).
(C) Left panel: genomic annotation of circRNAs. Right panel: structural annotation of circRNAs mapping to coding regions is shown.
(D) Overlap of unique circRNAs in human and mouse samples before and after (left and right) filtering for expression level higher than five unique reads in human
samples.
See also Figure S1 and Table S1.induced to differentiate into myotubes (differentiation medium,
DM). Paired-end ribominus RNA sequencing (RNA-seq) was
performed, and the FindCirc computational pipeline (Memczak
et al., 2013) was applied in order to detect circRNAs. RNA-seq
data were first processed for gene expression analysis: reads
were mapped with TopHat and the transcriptome was reconsti-
tuted with Cufflinks (data summarized in Figure S1A). Differen-
tial gene expression analysis was performed in order to check
the quality of the in vitro differentiation experiments. While frag-
ments per kilobase of transcript per million mapped reads
(FPKMs) of genes in technical replicates were almost perfectly
correlated (>98% correlation; Figure S1B, upper panels), gene
expression in myotubes compared to myoblasts was highly
diverse, with >3,000 genes significantly upregulated or down-
regulated in one of the two conditions, in both human and
mouse systems (Figure S1B, lower panels). When looking at
the enrichment of gene products upregulated in myotubes
versus myoblasts in terms of gene ontology (GO) biological
process keywords, we found a consistent and significant
enrichment for genes related to muscle differentiation and
function (Figure S1C). Moreover, the expression of well-known
specific markers of muscle differentiation was assessed byqRT-PCR, which confirmed the data obtained by RNA-seq
(Figure S1D).
RNA-seq readswere then realigned to the reference genomes,
the ones contiguously aligned were discarded, and the remain-
ing reads were used as input for FindCirc (Figure 1A) to detect
head-to-tail splicing sites. As described in Figure 1B, thousands
of circular splicing events were found in both human and mouse
samples, with almost 90% deriving from internal exons of pro-
tein-coding genes (Figure 1C). Almost 10% of circRNAs was ex-
pressed at similar or higher levels with respect to the linear coun-
terpart (by comparing the number of reads mapping on circular
versus linear splice junctions). Interestingly, almost 600 of these
circRNAs were conserved between species of the 2,100 and
1,600 circRNAs identified in human and mouse, respectively
(Figure 1D, full list in Table S1). Our criterion for conservation
was any circRNA in which the genomic location in human over-
lapped with the syntenic region in mouse. Considering that
low-abundance species might have been missed by this anal-
ysis, the actual species overlap may be even higher. Indeed,
when filtering human circRNAs for high expression level (more
than five reads), the overlap with mouse circRNAs increased
from 25% to 40%.Molecular Cell 66, 22–37, April 6, 2017 23
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Figure 2. Differential CircRNAExpression in
Human Myoblast Differentiation and Dis-
ease
(A) Scatterplots showing reads mapping to highly
expressed circRNA junctions in two myoblast
(GM, A and B, left) and myotube (DM, A and B,
right) replicates.
(B)Heatmapshowing expression levels of selected
circRNAs inWTandDMDmyoblasts (GM, A andB)
and myotubes (DM, A and B). Values are normal-
ized as row Z scores.
(C) Scatterplot showing circular/linear (C/L) ratio in
GM versus DM, calculated as log2 of the number
of reads mapping to a circular junction divided by
the mean of reads mapping linearly at the same
genomic coordinates.
(D) Empirical cumulative distribution of the C/L
ratio in GM (blue) and DM (red).
(E) Scatterplot of fold change of reads mapping to
circRNA junctions versus reads mapping to linear
junctions at the same coordinates. Linear regres-
sion is shown in red. Black lines correspond to a
fold change of 2.
(F) Bar plot representing fold change of circRNA
expression in myotubes versus myoblasts (DM/
GM) grouped by differential expression of host
gene according to Cuffdiff FPKMs. Two and three
asterisks indicate a Wilcoxon-Mann-Whitney test-
derived p value below 0.02 and 0.01, respectively.
Up, upregulated genes; Eq, non-differentially ex-
pressed genes; down, downregulated genes (fold
change > 2).
(G) Left panels: coverage plots of genomic loci of
circ-BNC2 and circ-CDYL. Right panels: bar plots
show reads mapping to circular (Circ) and linear
(Lin) splice sites for circ-BNC2 and circ-CDYL in
GM (blue bars) and DM (red bars).
See also Figure S2 and Table S1.CircRNA Expression Is Modulated in Muscle
Differentiation and Disease
To perform quantitative analyses on circRNA expression and
regulation, we took human samples and reduced further our
list to a set of highly expressed molecules by requiring at least
five unique reads mapping to the head-to-tail junction. With this
threshold, while the technical replicates had an overall very24 Molecular Cell 66, 22–37, April 6, 2017good correlation (Figure 2A), the compari-
sonbetweenmyoblasts andmyotubes re-
vealedaglobal change in circRNAexpres-
sion (45% circRNAs having R2-fold
variation in one of the two conditions, Fig-
ure 2B), meaning that these molecules
were modulated in response to cell differ-
entiation. RNA-seq data from human
myoblasts derived from DMD patients
were also analyzed. Hierarchical clus-
tering analysis of normal and dystrophic
myoblasts and myotubes revealed that
indeedDMDcells have a unique signature
in termsof circRNA expression levels (Fig-
ure 2B): specific subsets of transcriptswere differently abundant in DMD with respect to controls both
in GM and in DM conditions. This is in agreement with the notion
that Duchenne cultures have a much slower progression into the
differentiation process (Cazzella et al., 2012). Notably, circRNA
abundance tends in general to increase during differentiation
(Figure 1B), as described for neuronal differentiation (Rybak-
Wolf et al., 2015). The circular/linear ratio also followed this trend
(Figures 2C and 2D). This is possibly related to the high stability
of these molecules: during differentiation, induction of circRNAs
at the transcriptional level, combined with a slow turnover, could
lead to their accumulation over time.
Then we addressed the question of whether modulation of
circRNA expression in myogenesis was due to transcriptional
regulation of the host gene or to post-transcriptional control,
such as competitive biogenesis between the linear and the circu-
lar isoforms within the same gene (Ashwal-Fluss et al., 2014).
Therefore, we analyzed the relationship between the fold change
ratio of circular versus linear expression level in the two condi-
tions tested (GM versus DM), and we found a positive correlation
(Figure 2E). Additionally, according to FPKMs calculated with
Cuffdiff, the abundance of circRNAs produced fromupregulated,
stable, or downregulated genes indicated that the induction of
circRNAs coming from upregulated genes was significantly
higher than that of stable and downregulated genes (Figure 2F).
However, exceptions were detected, such as the BNC2 gene
that producesmainly the linearmRNA in human andmousemyo-
blasts in growth conditions but predominantly the circRNA in
differentiated cells. Figure 2G shows circ-BNC2 in comparison
with circ-CDYL, which is an example of a concomitant increase
in both circular and linear isoforms during myogenesis, probably
because of transcriptional activation of the locus.
RNAi-Based CircRNA Functional Screening
Specific criteria were applied in order to restrict the number
of candidates for further characterization: (1) conservation, (2)
expression level, (3) modulation during differentiation, and (4) cir-
cular/linear ratio (see the STARMethods). This filtering yielded 31
circRNAs,which are shown in Table 1. The selected specieswere
initially validatedbyRT-PCR (summarized in Table 1, full results in
Figures S2A and S2B, list of primers in Table S2). Of 31 candi-
dates, only one, circ-MYL4, was not detected as a band of the
expected size in human samples. Circ-TTTY16 was instead not
detected in mouse samples, because it is located in the Y chro-
mosome, which is not present in C2C12 cells. For almost every
circRNA, RT-PCR produced a band of the expected size and
one or more larger products, possibly corresponding to conca-
temers generated by rolling circle retro-transcription. For a
few circRNAs (CDYL, QKI, and ZNF609), we gel-extracted and
sequenced those bands, confirming that they contained the
head-to-tail junction and that they were concatemers (Fig-
ure S2C). The qRT-PCR analysis of a subset of six human
circRNAs did not reveal a major second PCR product for any of
them (Figure S2D), possibly because of the different enzyme
and cycling conditions used with respect to non-quantitative
PCRandopening to thepossibility of using such technique for ac-
curatemeasurement of relative circRNA expression (Figure S2E).
Indeed, in all cases, the normalized RNA quantities measured by
qRT-PCR reflected the levels observed byRNA-seq andRT-PCR
(Figure S2E). For the same candidates, purification of total RNA
with oligo dT revealed that they were preferentially recovered in
the non-polyadenylated fraction with respect to their linear coun-
terparts (FigureS2F). Similarly, comparison of dT- versus random
examer-primed cDNAsynthesis shows that circRNAswere retro-
transcribed more efficiently with random examers than with dT
with respect to linear RNAs (Figure S2G).Resistance to the RNase R exonuclease was used to test
whether the selected molecules were circular (Suzuki et al.,
2006).Of 30putative circRNAs, 29wereconfirmedasnon-acces-
sible to the exonuclease. Only one, circ-NEB, was digested by
RNase R as efficiently as its linear counterpart (summarized in
Table 1, full results in Figures S2H and S2I). Moreover, nuclear/
cytoplasmic fractionation indicated that all circular species
were almost exclusively located in the cytoplasm, both in mouse
and human cells (Figures S2J and S2K).
We then designed an image-based functional genetic screen
to further characterize these molecules (summarized in Fig-
ure 3A). We tried to design at least two small interfering RNAs
(siRNAs) targeting each of the 29 circRNAs, according to the
following features: (1) binding site at the head-to-tail junction;
(2) 7-mer seed not present in the linear host gene; and (3) chem-
ical modifications within the seed region, in order to reduce
the chance of an miRNA-like effect and passenger strand inacti-
vation to direct strand-specific Ago loading. These modifica-
tions and their applications have been the objective of extensive
studies (Jackson et al., 2006; Chen et al., 2008), and they have
been here designed for customized targets (On-Target-plus by
Dharmacon). Following these rules, it was possible to design
two siRNAs for 20 circRNAs, one for five circRNAs, and none
for the four remaining ones (Figure S3A; siRNAs listed in Table
S3). Due to the poor transfectability of human primarymyoblasts,
we developed a reverse transfection protocol that allowed
high-efficiency transfection of siRNAs in these cells (see the
STAR Methods). The 45 siRNAs plus a negative control were
applied in triplicate to myoblast cultures in a 96-well format,
and, 24 hr post-transfection, cells were switched to DM for 48
and 96 hr. The relative abundance of the circular versus linear
forms was tested in order to confirm the specific downregulation
of the circRNA. This revealed that at least one siRNA for 17
different genes specifically downregulated the circular form
without affecting the linear mRNA (Figure S3B).
Immunofluorescence analysis was performed for two com-
mon myogenic markers, Myogenin (MYOG) and Myosin Heavy
Chain (MHC), together with DAPI staining (Figure S3C). Several
readouts were analyzed in order to obtain a detailed picture of
how knockdown of each circRNA affected cell differentiation
and morphology. We included in this analysis 11 different phe-
notypes, including total cell number, the fraction of MYOG- or
MHC-positive cells, and additional morphological parameters,
such as the fusion index. From this screening, two strong
and opposite phenotypes associated with siRNAs targeting
circ-QKI and BNC2 emerged. The two siRNAs designed for
circ-QKI (siRNA #1 and siRNA #2) both inhibited myoblast dif-
ferentiation (Figure 3B). While siRNA #1 had a specific effect
on circ-QKI and none on QKI mRNA, siRNA #2 did not alter
circ-QKI levels but downregulated QKI mRNA (Figure S3B).
This supports the hypothesis that both circ-QKI and QKI
mRNA participate in the same process. To confirm that
hypothesis, we raised a third siRNA specifically targeting QKI
mRNA (si-QKI-L; Figure S3D). si-QKI-L, and additional experi-
mental replicates with si-QKI #1 (Figures 3C, S3B, S3D, and
S3E), had again a specific anti-myogenic effect, thus confirming
that both the circRNA and the mRNA could be involved in
promoting differentiation (Figure S3E, as in Li et al., 2003).Molecular Cell 66, 22–37, April 6, 2017 25
Table 1. The Selected 31 CircRNAs and Summary of Their Experimental Validation
Human CircRNAs in Human Myoblasts Cells
CircRNA Chromosome Start End Reads (GM A, GM B,
DM A, DM B)
RT-PCR RNase R Cyt/Nuc
Circ-ACVR2A chr2 148653869 148657467 0, 3, 10, 7 yes yes cyt
Circ-ADAMTS6 chr5 64747301 64769779 37, 34, 0, 5 yes yes cyt
Circ-ANKIB1 chr7 91924202 91957214 0, 3, 6, 6 yes yes cyt
Circ-ASH1L chr1 155408117 155408859 6, 5, 2, 0 yes yes cyt
Circ-ASPH chr8 62531536 62566219 3, 0, 2, 0 yes yes cyt
Circ-BACH1 chr21 30693541 30702014 11, 12, 9, 4 yes yes cyt
Circ-BNC2 Chr9 16435552 16437522 0, 0, 8, 7 yes yes cyt
Circ-CAMSAP1 Chr9 138773478 138774924 15, 8, 16, 17 yes yes cyt
Circ-CDYL Chr6 4891946 4892613 10, 12, 18, 21 yes yes cyt
Circ-CRKL Chr22 21288066 21288532 0, 2, 10, 8 yes yes cyt
Circ-DCBLD2 chr3 98568304 98600611 27, 31, 3, 4 yes yes cyt
Circ-HIPK3 Chr11 33307958 33309057 88, 82, 90, 93 yes yes cyt
Circ-MED13L Chr12 116668337 116675510 10, 7, 5, 16 yes yes cyt
Circ-MEF2A Chr15 100211527 100215663 0, 0, 2, 0 yes yes cyt
Circ-MYL4 Chr17 45297314 45297419 0, 0, 4, 8 no N/A N/A
Circ-NEB chr2 152544139 152550950 0, 0, 18, 34 yes no N/A
Circ-PMS1 chr2 190656515 190682906 3, 0, 7, 3 yes yes cyt
Circ-PTP4A2 chr1 32381495 32385259 6, 12, 9, 15 yes yes cyt
Circ-QKI chr6 163876310 163956157 0, 0, 7, 8 yes yes cyt
Circ-RTN4 chr2 55252221 55255356 0, 0, 4, 6 yes yes cyt
Circ-RTN4bis chr2 55209650 55214834 10, 13, 22, 20 yes yes cyt
Circ-RUNX1 Chr21 36206706 36231875 0, 2, 9, 7 yes yes cyt
Circ-SEPT9 chr17 75398140 75398785 3, 0, 7, 3 yes yes cyt
Circ-SLC8A1 chr2 40655612 40657444 71, 53, 12, 13 yes yes cyt
Circ-SPECC1 chr17 20107645 20109225 7, 5, 12, 6 yes yes cyt
Circ-TMEFF1 chr9 103261046 103279053 3, 0, 5, 7 yes yes cyt
Circ-TTN chr2 179557223 179558735 0, 0, 2, 3 yes yes cyt
Circ-ZFHX3 chr16 72984367 72994093 3, 2, 2, 0 yes yes cyt
Circ-ZNF292 chr6 87920169 87928449 8, 11, 11, 6 yes yes cyt
Circ-ZNF609 chr15 64791491 64792365 13, 4, 12, 8 yes yes cyt
Circ-TTTY16 chrY 7565120 7567528 2, 0, 0, 2 yes yes cyt
Mouse CircRNAs in C2C12 Cells
CircRNA Chromosome Start End Reads (GM A, GM B,
DM A, DM B)
RT-PCR RNase R Cyt/Nuc
Circ-Acvr2a chr2 48870288 48873473 0, 0, 4, 6 yes yes cyt
Circ-Adamts6 chr13 104294446 104314383 0, 2, 2, 5 yes yes cyt
Circ-Ankib1 chr5 3747020 3772787 0, 4, 14, 13 yes yes cyt
Circ-Ash1l chr3 89001772 89007877 0, 0, 5, 3 yes yes cyt
Circ-Asph chr4 9583811 9610938 0, 0, 5, 4 yes yes cyt
Circ-Bach1 chr16 87715330 87722608 2, 0, 0, 2 yes yes cyt
Circ-Bnc2 chr4 84291692 84293662 2, 2, 12, 19 yes yes cyt
Circ-Camsap1 chr2 25965662 25966948 0, 0, 8, 7 yes yes cyt
Circ-Cdyl chr13 35815908 35816575 7, 5, 19, 25 yes yes cyt
Circ-Crkl chr16 17468892 17469358 0, 0, 1, 0 yes yes cyt
Circ_Dcbld2 chr16 58424560 58433463 5, 10, 2, 6 yes yes cyt
Circ-Hipk3 chr2 104470748 104471847 5, 7, 43, 42 yes yes cyt
(Continued on next page)
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Table 1. Continued
Human CircRNAs in Human Myoblasts Cells
CircRNA Chromosome Start End Reads (GM A, GM B,
DM A, DM B)
RT-PCR RNase R Cyt/Nuc
Circ-Med13l chr5 118593332 118593570 6, 4, 17, 27 yes yes cyt
Circ-Mef2a chr7 67264864 67268400 0, 0, 8, 3 yes yes cyt
Circ-Myl4 chr11 104584022 104584127 0, 0, 6, 3 yes yes cyt
Circ-Neb chr2 52299476 52305391 0, 0, 39, 37 yes no N/A
Circ-Pms1 chr1 53256628 53282092 0, 4, 6, 8 yes yes cyt
Circ-Ptp4a2 chr4 129838977 129846539 2, 0, 0, 0 yes yes cyt
Circ-Qk chr17 10238892 10282981 0, 0, 2, 0 yes yes cyt
Circ-Rtn4 chr11 29705534 29708770 2, 3, 6, 13 yes yes cyt
Circ-RTN4bis chr11 29733632 29736498 0, 0, 0, 2 yes yes cyt
Circ-Runx1 chr16 92644153 92668812 0, 0, 5, 6 yes yes cyt
Circ-Sept9 chr11 117290397 117291036 2, 2, 9, 9 yes yes cyt
Circ-Slc8a1 chr17 81647808 81649638 0, 0, 12, 16 yes yes cyt
Circ-Specc1 chr11 62117699 62119282 0, 2, 0, 0 yes yes cyt
Circ-Tmeff1 chr4 48604580 48617331 0, 2, 6, 5 yes yes cyt
Circ-Ttn chr2 76766305 76791371 0, 0, 3, 7 yes yes cyt
Circ-Zfhx3 chr8 108792201 108800691 2,3,4,3 yes yes cyt
Circ-Zfp292 chr4 34839331 34839986 0,0,12,14 yes yes cyt
Circ-Zfp609 chr9 65794621 65795495 0,0,10,7 yes yes cyt
Circ-Ttty16 N/A N/A N/A N/A N/A N/A N/A
Columns contain: gene name, genomic coordinates (hg19 for human and mm10 for mouse) of the head-to-tail splice junction, number of reads map-
ped to the splice junction in human or mouse myoblasts (GM A and GM B) and myotubes (DM A and DM B), RT-PCR validation (yes if bands of the
expected size were obtained and no if not), RNase R resistance (yes if the fraction of recovery after RNase R treatment of the circular form was signif-
icantly higher than for the linear form and no if not), and subcellular localization. ‘‘N/A’’ applies to the murine circ-Ttty16, where it was not detected
because the host gene is located in the Y chromosome, which is missing in C2C12 cells. cyt, cytoplasm; nuc, nucleus.In the case of circ-BNC2, si-BNC2#1efficiently downregulated
circ-BNC2 but had also a small effect on BNC2 mRNA, while si-
BNC2 #2 targeted specifically circ-BNC2 and had no effect on
the phenotype (Figure S3B). These data suggested that the
observed phenotype was likely associated with BNC2 mRNA
knockdown. We confirmed this by using a third siRNA, designed
specifically for BNC2 mRNA (si-BNC2-L; Figures S3D and S3E),
and we observed the same effect as with additional replicates
of si-BNC2 #1 (Figures 3C, S3D, and S3E). Notably, during differ-
entiation, a strong increase of the circular RNA paralleled the
decrease of the linear BNC2 mRNA (Figures 2G, S2A, and S2B).
Therefore, it is likely that biogenesis of circ-BNC2 is amechanism
for competing with the production of the anti-myogenic BNC2
mRNA when differentiation starts.
Interestingly, both circRNAs, upregulated during in vitro differ-
entiation of control myoblasts, were downregulated in DMD
conditions (Figure 3D), well correlating with the notion that
dystrophic cells have altered progression into the differentiation
process (Cazzella et al., 2012). For a different set of circRNAs
highly expressed in myoblasts, we investigated the relationship
between their abundance and proliferation capacity through a
bromodeoxyuridine (BrdU)-labeling assay (Figure S3C). Among
the circRNAs tested, we found that the knockdown of circ-
ZNF609 (successfully accomplished with siRNA #1) reduced
BrdU incorporation by 80% (Figure 4A). In line with this, also
markers of proliferation, such as CDK1 and cyclin A2, weresignificantly reduced after circRNA knockdown (Figure 4E),
indicating a specific role of circ-ZNF609 in myoblast prolifera-
tion. Similar effects, even if at lower extents, were observed in
murine cells (Figures S4A and S4B). The initial screening was
subsequently validated by comparing the activity of three
distinct siRNAs: si-circ (corresponding to siRNA #1 used in the
screening), which targets the circ-ZNF609 head-to-tail junc-
tion; si-ex2, targeting both the circRNA and its linear counter-
part; and si-mRNA targeting only the linear mRNA (Figure 4B).
Both si-circ and si-ex2 reduced myoblast growth rate by 80%
while si-mRNA, targeting only the linear mRNA, did not affect
proliferation (Figures 4C and 4D). These results allowed us to
exclude that the observed phenotype was due to an off-target
effect, and they indicated that the decrease in proliferation
was solely due to the circRNA activity. Both circular and linear
ZNF609 RNA levels were measured after treatments by qRT-
PCR, confirming the specificity of the three siRNAs (Figure 4E).
Moreover, northern blot analysis confirmed that circ-ZNF609
was susceptible to si-circ treatment and resistant to RNase
R (Figure 4F), while the linear ZNF609 mRNA was resistant to
si-circ and susceptible to RNase R (Figure 4F). Notably, the cir-
cular form co-migrated with the product derived from an artificial
construct, p-circ (see next paragraph), overexpressing circ-
ZNF609 RNA (Figure 4F).
Also interestingly, circ-ZNF609, which is downregulated dur-
ing myogenesis in control myoblasts, was instead found atMolecular Cell 66, 22–37, April 6, 2017 27
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elevated levels in DMD conditions (Figure 4G). This is consistent
with the delayed differentiation phenotype of dystrophic primary
myoblasts and with the persistence of a high proportion of prolif-
erating, non-fusing myoblasts (Cazzella et al., 2012). These data
reinforce further the connection of circ-ZNF609 and myoblast
proliferation.
Circ-ZNF609 Encodes a Protein
Circ-ZNF609 originates from the circularization of the second
exon of its host gene. A 753-nt open reading frame (ORF) is
present in circ-ZNF609, spanning from the putative AUG of the
host gene to a STOP codon created 3 nt after the splice junction
(Figure 5A). To determine whether this ORF (circORF) is func-
tional, we first used sucrose gradient fractionation to test circ-
ZNF609 loading onto polysomes. Figure 5B shows that a small
but significant proportion of circ-ZNF609 sedimented with heavy
polysome fractions while the rest remained in the non-bound
fraction. The circular conformation of the polysome-bound
circ-ZNF609 RNA was confirmed by RNase R resistance (Fig-
ures S5A and S5B). Moreover, we excluded the presence of
possible linear concatemers by northern blot (Figure 4F; see
also RT-PCR with primers in exons 1 and 3 of the ZNF609
gene in Figure S5C). In puromycin-treated myoblasts, circ-
ZNF609 shifted to lighter polysomes, similarly to the behavior
of the linear ZNF609 and HPRTmRNAs, suggesting that its sedi-
mentation pattern was due to active translation. As a control, a
circRNA with no ORF, circ-PMS1, remained on free RNA frac-
tions. The association of circ-ZNF609 with heavy polysomes
was also confirmed in mouse (Figure S5D).
To test the protein-coding ability of circ-ZNF609, we took
advantage of an expression vector that was able to produce cir-
cular transcripts (Kramer et al., 2015). P-circ contains the second
exon of the ZNF609 gene and is able to express circ-ZNF609
RNA at high levels (Figure 4F). Sequencing of the RNA produced
from this construct revealed its perfect correspondence with the
endogenous circ-ZNF609 RNA (data not shown). A construct
was derived from p-circ that contained a 33FLAG-coding
sequence immediately upstream of the STOP codon, such that
a flagged protein could be produced only upon formation of a cir-
cular template (p-circ3xF; Figure 6A). Due to the poor transfec-
tion efficiency of plasmid DNA in human and murine myoblasts,
the following experiments were carried out in HeLa and N2A
cells. The results indicate that in both cell types, in comparison
to mock-treated cells, p-circ3xF gave rise to two flagged pro-
teins (Figure 6B). Inspection of the sequence indicated that a
second ATG codon was present 150 nt downstream of the first
one and in the same frame. Mutants lacking either one of theFigure 3. CircRNA Knockdown followed by Phenotypic Screening in H
(A) Experimental workflow of the phenotypic screening strategy.
(B) Heatmap showing selected phenotypes in color scale after Z score normaliz
column indicates one phenotype and each row indicates one sample. The numb
(C) Human primary myoblasts were treated with either a control scramble siRNA (s
and induced to differentiate for 48 (upper panels) and 96 hr (lower panels). A repres
is shown.
(D) RNA levels measured by qRT-PCR of circ-QKI and circ-BNC2 in human cont
from biological triplicates of two WT (light gray bars) and three DMD primary cel
See also Figure S3 and Table S3.two initiation codons (p-circD1 and p-circD2) showed that two
bands observed by western blot corresponded to two isoforms:
the upper band (ATG1) derived from translation from the first
ATG, while the lower one (ATG2) originated from the second start
codon (Figure 6B). Deletion of both ATGs (p-circD1-2) abolished
both products. An additional mutant, with a TGA Stop codon re-
placing ATG2 (Figure 6A; STOP2), confirmed that translation of
the flagged proteins required initiation at those precise sites
(Figure S6C).
An additional construct, p-lin3xF, was raised carrying the
same ORF present in circ-ZNF609 in a linear conformation.
When transfected in HeLa and N2A cells, this plasmid induced
the expression of the same two proteins observed with the
circular substrate, even if with a much higher efficiency
(Figures S6A and S6B). Moreover, the flagged protein resulted
in nuclear localization (Figure S6C). Titration of the proteins
produced by the linear versus the circRNAs, normalized for
the amount of RNA produced, indicated that circRNA was
translated at almost two orders of magnitude lower efficiency
than the linear form (Figure S6B). These results are in line with
previous observations showing that re-initiation and internal
initiation of translation can be as low as 1%–10% the effi-
ciency of cap-dependent initiation (Merrick, 2004). Moreover,
while the circular template yielded approximately the same
amount of the two isoforms, translation of the linear one was
strongly biased in favor of the first ATG, indicating a substan-
tial difference in the translation initiation mechanism between
the circular and linear transcripts.
In cells expressing p-circ3xF and the different ATG mutant
derivatives, we confirmed the production of circular tran-
scripts by northern analysis (Figure S6D), with a specific con-
trol of RNase R resistance (Figure S6E). We also verified the
integrity of the ORF by Sanger sequencing of the RT-PCR
products (data not shown), and we further excluded the pro-
duction of linear concatemers through RT-PCR (Figures S6F
and S6G).
To further prove the protein-coding ability of the circ-
ZNF609 RNA derived from the chromosomal gene, we designed
a genome-editing approach for inserting the 33FLAG-coding
sequence in the endogenous ZNF609 locus. We used the
CRISPR/Cas9 system in mouse embryonic stem cells in combi-
nation with a DNA donor designed for inserting the 33FLAG-
coding sequence in the same position as in p-circ3xF, so that
a flagged protein could be produced only upon circularization
of the second exon of ZNF609 (Figure 6D). After transfection,
clonal selection, and genotypization (Figures S6H–S6J), we ob-
tained one positive clone carrying two modified alleles: the firstuman Primary Myoblasts
ation. High values are shown in blue while low values are shown in red. Each
er of detected significant phenotypes is shown in red scale on the right.
i-SCR) or with siRNAs against circ-QKI (si-QKI #1) and circ-BNC2 (si-BNC2 #1)
entative immunofluorescence for MYOG andMHC together with DAPI staining
rol (WT) and Duchenne (DMD) myocytes. RNA measurements were performed
l lines (dark gray bars).
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one contained the expected flagged allele, while the second car-
ried a small deletion across the 30 splice site of the first intron,
which prevented circularization of the second exon (Figure S6J;
F/D clone). Therefore, from this cell line only the flagged allele
would be able to produce the circ-ZNF609 RNA, and the amount
of circRNA produced would be half of that produced by a wild-
type (WT) line. Since circ-ZNF609 is highly expressed in neural
tissues (Rybak-Wolf et al., 2015), we applied an established
neuronal differentiation protocol (Wichterle and Peljto, 2008),
and we checked for the expression of the FLAG-tagged circ-
ZNF609 RNA by northern blot in WT cells and in the F/D clone.
As expected for their genomic context, F/D cells produced
roughly half the circRNA of WT cells (Figure S6K); moreover,
the circRNA was slightly larger than in the WT because of the in-
serted tag. RT-PCR and Sanger sequencing confirmed that the
circ-ZNF609 RNA produced by F/D cells was identical to that
made by the p-circ3xF construct. Due to the low translation
efficiency and the high background in western analysis, we per-
formed immunoprecipitation of F/D cells lysates with an anti-
FLAG antibody, and then we subjected proteins (size selected
between 30 and 40 kDa) to mass spectrometry on a polyacryl-
amide gel. As positive controls, we immunoprecipitated pro-
teins from cells transfected with the constructs overexpressing
either the linear or the circular flagged ORF. Figure 6E shows
that numerous peptides, mapping to the circORF, were present
in overexpression conditions with the linear construct (p-lin3xF),
fewer with overexpression of the p-circ3xF construct, and one in
the F/D sample. This is in agreement with the lower levels of RNA
produced by the chromosomal gene, with respect to those ob-
tained with the overexpression of both p-circ3xF (Figure 4F)
and p-lin3xF, and to the lower translational efficiency from circu-
lar templates (Figures S6A and S6B). No ZNF609 peptides were
instead detected in control WT cells.
As low initiation efficiency is commonly associated with cap-
independent translation, which instead serves as a regulatory
mechanism responding to various external stimuli, such as
heat shock stress (Holcik and Sonenberg, 2005), we tested pro-
tein production in such condition. As shown in Figure 6F, heatFigure 4. Circ-ZNF609 Controls Myoblast Proliferation
(A) Human myoblasts were treated with either a control siRNA (si-Scr) or with siRN
The color scale represents the percentage of BrdU-positive cells measured in tr
(B) Schematic representation of the siRNAs used for circ-ZNF609 phenotype valid
siRNA targeting both the circRNA and the linear mRNA is shown in green (si-ex2
(C) Human primary myoblasts were treated with either a control scramble siRNA
BrdU is shown in red and DAPI staining is shown in blue.
(D) Percentage of BrdU incorporation levels in cells treated as in (C).
(E) RNA quantification by qRT-PCR of circ-ZNF609, ZNF609 mRNA, and two ma
siRNAs as in (C).
(F) Left panel: schematic representation of the DIG-labeled probe used for north
ZNF609 RNAs. Right panel: northern blots on 20 mg total RNA from primary myo
shown. The linear and the circular RNA forms are indicated aside the gels with the ‘
20 mg total RNA frommyoblasts with the addition of 1 mg RNA from HeLa cells tran
ZNF609 (p-circ). Each blot is shown in parallel to the EtBr staining of the agaros
(G) RNA levels measured by qRT-PCR of circ-ZNF609 in human wild-type (WT) a
performed from biological duplicates of two WT and three DMD primary myobl
stated. One asterisk indicates a Student’s t test-derived p value < 0.05, two aste
mean and SE.
See also Figure S4.shock induces a strong and significant increase in translation
of the flagged circ-ZNF609 transcript.
IRES Activity of Circ-ZNF609 UTR
Since circRNAs are devoid of cap structure, translation should
occur through sequences able to act as internal ribosome en-
try sites (IRESs). Notably, phylogenetic analysis of the 50 and
30 UTRs of ZNF609 in vertebrates indicated that the portion
of the 50 UTR present in circ-ZNF609 was significantly more
conserved than the other UTR sequences situated in the linear
ZNF609 mRNA (Figure S6L). To test whether it possessed
IRES-like activity, the circ-ZNF609 UTR was inserted between
the Firefly and Renilla luciferases of a bicistronic construct
(UTR; Figure 6G). With respect to a vector containing a viral
IRES sequence (EMCV), UTR displayed very little luciferase
activity (Figure 6H). Remarkably, Renilla luciferase raised to
levels even higher than those of EMCV when introns from
ZNF609 (UTR-inZNF), HPRT (UTR-inHPRT), and b-globin
(UTR-inbglob) genes were inserted into the UTR construct, re-
constituting the original splice junction of circ-ZNF609.
Furthermore, deletion of the 50 splice site in UTR-inbglob
(UTR-Dss) completely abolished luciferase levels (Figure 6H),
indicating that Renilla luciferase (Rluc) activity did not originate
from cryptic splice sites and ultimately proving the relevance
of splicing in the induction of IRES activity. Finally, the circ-
ZNF609 UTR was replaced with an unrelated sequence of
similar length (MCS-inbglob). Notably, this construct was not
able to trigger Rluc activity (Figures 6G and 6H), thus pointing
out that IRES activity also relies on specific features of the
UTR sequence. RT-PCR analysis indicated that correct
splicing, where applicable, was obtained for all constructs
(Figure S6M). Altogether, these data show that the UTR of
circ-ZNF609 is able to work as an IRES in a splicing-depen-
dent manner.
Moreover, syntheticFLAG-taggedcirc-ZNF609madeby invitro
ligation (Figure S6N) was not translated upon transfection in com-
parison to the same molecule produced through back-splicing
from plasmid p-circ3xF, further demonstrating the requirementAs against the circRNA indicated; cells were maintained in growth conditions.
iplicate.
ation. The siRNA targeting specifically the circRNA is shown in red (si-circ), the
), and the siRNA targeting only the mRNA is shown in blue (si-mRNA).
(si-Scr) or the siRNAs shown in (B). A representative immunofluorescence for
rkers of cell-cycle progression (CDK1 and Cyclin A2) after treatment with the
ern blot analysis together with its location on the circular and linear forms of
blasts treated with either siRNAs (si-Scr and si-circ) or RNase R (– and +) are
‘–’’ and ‘‘o’’ symbols, respectively. As a control, northern blot was performed on
sfected with either an empty vector (mock) or a construct overexpressing circ-
e gel, where the migration of the 18S and 28S rRNAs is indicated.
nd Duchenne (DMD) myoblasts upon differentiation. RNA measurements were
asts. All values derive from three independent experiments unless differently
risks indicate a p value < 0.02, and three asterisks a p value < 0.01. Bars show
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Figure 5. Circ-ZNF609 RNA Is Associated with Polysomes
(A) Schematic representation of the following: ZNF609 pre-mRNA (center), ZNF609 mRNA (above), and ZNF609 s exon (below) from which circ-ZNF609 (right)
originates. The 50 and 30 UTRs are indicated by smaller boxes, while the coding region (CDS) is represented by larger boxes. Start and stop codons are shown in
green and red, respectively.
(B) Cytoplasmic extracts from proliferating humanmyoblasts, either untreated (native, black) or treated with puromycin (gray), were loaded on 15%–50%sucrose
gradients. Absorbance at 253 nm was measured and fractions were collected. Fraction density decreases from left to right; the panels show one representative
profile of three independent biological replicates. Individual fractions were analyzed by qRT-PCR and are represented as a percentage of total RNA in each
fraction. Profiles are shown for circ-ZNF609 and ZNF609 mRNA. Circ-PMS1 and HPRT mRNA represent negative and positive controls, respectively.
See also Figure S5.
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Figure 6. Circ-ZNF609 Has Protein-Coding Activity
(A) Schematic representation of the p-circ3xF construct. The second exon of the ZNF609 gene was cloned in a plasmid carrying inverted repeats (IRs) from the
ZKSCAN1 gene (see the STAR Methods) in order to achieve circularization. A 33FLAG tag was inserted upstream to the stop codon in order to obtain a flagged
protein after circularization. Mutant derivatives with deleted ATGs are shown below. Start and stop codons are shown in green and red, respectively. A 33FLAG-
coding sequence is shown in blue.
(B) Western blot analysis with an anti-FLAG antibody on proteins from HeLa (human) and N2a (mouse) cells transfected with p-circ3xF and its mutant derivatives.
GAPDH was used as a loading control.
(legend continued on next page)
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of a splicing-dependent process for efficient circRNA translation
(Figures S6N and S6O).
DISCUSSION
Due to several unique features, circRNAs are increasingly recog-
nized as promising candidates for the identification of additional
layers of gene expression control. For instance, circRNAs can
pleiotropically modulate gene expression by competing for
miRNA or protein binding (Hansen et al., 2013; Hentze and Pre-
iss, 2013; Du et al., 2016), or they can compete with linear RNA
production regulating the accumulation of full-length mRNA
(Ashwal-Fluss et al., 2014). They have been shown to have differ-
ential tissue-specific expression (Memczak et al., 2013; Rybak-
Wolf et al., 2015) and specific subcellular localization (Rybak-
Wolf et al., 2015; You et al., 2015). Despite the large number of
circRNAs identified in many different organisms, tissues, and
developmental conditions, only a few examples are available
that indicate a crucial role on cellular functions (Guarnerio
et al., 2016; Yang et al., 2016). In part this is due to the difficulty
in selective targeting of circRNAs, because their nature limits
the choice of target region for selectivity and further constrains
the parameters normally used for designing mRNA-targeting
siRNAs.
Here, with a combination of bioinformatic tools, we obtained
selective circRNA downregulation using modified siRNAs.
These reagents were used in an image-based functional genetic
screen of 25 circRNA species, conserved between mouse and
human, which were differentially expressed during myogenesis.
Such analysis provided one interesting case, circ-ZNF609,
whose phenotype could be specifically attributed to the circular
form and not to the linear counterpart. Notably, analysis of the
circ-ZNF609 sequence revealed the presence of an ORF. We
found that a fraction of circ-ZNF609 RNA is loaded onto poly-
somes and that, upon puromycin treatment, it shifted to lighter
fractions, similar to canonical mRNAs. The coding ability of
this circRNA was proved through the use of artificial constructs
expressing circular tagged transcripts and by CRISPR/Cas9(C) Western blot analysis with an anti-FLAG antibody on proteins from HeLa cells
was used as a loading control.
(D) Schematic representation of the genome-editing approach for tagging the e
mology-directed repair of a CRISPR/Cas9-induced double-strand break (DSB) w
upstream of the stop codon in exon 2. The edited cells were cultured and harveste
(size selected between 30 and 40 kDa) and subjected to mass spectrometry.
(E) Individual peptides detected by mass-spec are depicted in orange at their ma
overexpression of the linear ORF (see Figure S6A) by p-lin3xF (top), overexpressi
endogenous locus (bottom).
(F) Representative western blot analysis with an anti-FLAG antibody on proteins
heat shock conditions. Circ-ZNF609 RNA levels were the same in both conditions
with Hsp70 and phosphorylated eIF2 alpha antibodies. Actinin was used as a loa
(G) Schematic representation of the luciferase bicistronic constructs used. The
luciferase-coding regions in the control construct (p-Luc). The spacer of p-Lucwas
or 80 nt from the 30 portion of the second exon fused to the UTR of circ-ZNF609 (U
ZNF609, HPRT, and b-globin (UTR-in ZNF/HPRT/bGlob.) genes. From UTR-in-bG
the 50 splice site, while MCS-inbGlob. carries an unrelated sequence in place of
(H) Luciferase activity derived from cells transfected with the constructs describe
Renilla versus Firefly activities. Three asterisks represent a Student’s t test-derive
show mean and SE.
See also Figure S6.
34 Molecular Cell 66, 22–37, April 6, 2017tagging of the endogenous ZNF609 gene. Proteins derived
from the translation of circRNAs were described a long time
ago in Archaea, where homing endonucleases were produced
by stable circularized introns (Kjems andGarrett, 1988; Dalgaard
et al., 1993). Although there are reports of circRNA in vitro trans-
lation (Chen and Sarnow, 1995) and of proteins derived from arti-
ficial circRNA constructs (Wang and Wang, 2015; Abe et al.,
2015), our data demonstrate that an eukaryotic endogenous
circRNA may encode for a protein.
Generation of protein isoforms via back-splicing and circular-
ization of selected exons from primary mRNA transcripts is
an intriguing mechanistic alternate to conventional alternative
splicing. Interestingly, termination codons present upstream of
the AUG initiation codon in linear mRNAs can be converted
into in-frame STOP codons upon circularization. Moreover, de-
pending on the distance of the STOP codon from the newly
formed junction, peptides with additional amino acids that are
absent from the linear form can be produced. Therefore, these
mechanisms enlarge the repertoire of protein domains that can
be derived from a primary transcriptional unit, and they increase
further the complexity of the genome output. This is particularly
interesting in consideration of the fact that many circRNAs
contain the canonical start codon of their host gene (735
circRNAs of 2,175 in our human dataset, well above the number
expected by chance).
So far, we have no hints on the molecular activity of the pro-
teins derived from circ-ZNF609 and as to whether they
contribute to modulate or control the activity of the counterpart
deriving from the linear mRNA. The zinc-finger protein 609 has
been described as a transcriptional factor characterized by
two zinc-finger domains. To date only limited information is avail-
able about its activity. It was detected as part of a protein inter-
action network dedicated to control embryonic stem cell (ESC)
pluripotency in Nanog-associated complexes (Gagliardi et al.,
2013) and as a direct interactor of Dax1 (Wang et al., 2006).
ZNF609 was also shown to be required for Rag1 and Rag2
expression in developing thymocytes (Reed et al., 2013). The
fact that the circ-ZNF609-encoded protein lacks the zinc-fingertransfected with pcDNA, p-circ3xF, and its mutant derivative p-STOP2. ACTN
ndogenous ZNF609 locus. Mouse embryonic stem cells were edited with ho-
ith a DNA donor carrying a 33FLAG-coding sequence (in blue) immediately
d for IP with an anti-FLAG antibody. The eluted proteins were run on SDS-PAGE
pping position onto the protein sequence. Mass-spec data are shown for the
on of the circular RNA from p-circ3xF (middle), and expression from the edited
from HeLa cells transfected with either pcDNA or p-circ3xF in normal (CTR) or
(data not shown). As controls of the heat shock response, blots were hybridized
ding control.
SV40 promoter drives the transcription of Firefly (F-Luc) and Renilla (R-Luc)
substitutedwith the IRES sequence of the Encephalomyocarditis virus (EMCV)
TR). From UTR, additional constructs were raised carrying one intron from the
lob. two other constructs were derived as follows: UTR-inDss has a deletion of
the UTR.
d in (G). Values from three independent experiments are expressed as ratio of
d p value < 0.01 between the value of each sample and the empty vector. Bars
domains would suggest different hypotheses on how it could
interfere or cope with the activity of the full-length isoform: it
could act as a dominant-negative competitor or as a modulator
of alternative ZNF609 complex formation. Interestingly, the
flagged protein derived from circ-ZNF609 exhibited mainly nu-
clear localization.
However, since the use of plasmids and other expression vec-
tors as well as naked RNA produced a non-specific block of
myoblast proliferation, we were unable to perform rescue exper-
iments and univocally link the circ-ZNF609 phenotype to its pro-
tein-coding capacity.
Another relevant aspect about circRNAs, lacking the cap
structure and the polyA tail, relates to the machinery and fac-
tors required for the assembly into translationally competent
complexes.Cap-independent translation, drivenby the so-called
IRES, was initially described in viral RNAs (Pelletier and Sonen-
berg, 1988) and subsequently identified also in cellular RNAs
(Weingarten-Gabbay et al., 2016). IRESs can act by various
mechanisms, including the formation of RNA structures, Wat-
son-Crick base pairing with the 18S ribosomal RNA, and often
in cooperation with IRES-transacting factors (ITAFs) (Komar
and Hatzoglou, 2011); moreover, putative cellular IRESs have
been suggested to play crucial roles in different developmental
conditions and in response to different types of stress (Holcik
and Sonenberg, 2005).
In this work, we showed that the UTR element of circ-ZNF609,
spanning from the termination to the initiation codons, can drive
IRES-dependent translation but only if produced through a
splicing event, suggesting that factors loaded on the transcript
upon splicing might play a crucial role in ribosome recognition
and translation initiation.
In this study, we have also observed that the circular tem-
plate had a much lower translation activity when compared
to the linear counterpart, a feature exhibited also when
analyzing the cell line carrying an endogenous flagged allele
obtained through CRISPR/Cas9 genome editing. Interestingly,
heat shock induced significant activation of the flagged circ-
ZNF609 translation. It is well known that cap-independent
initiation is less efficient than the cap-dependent one (Merrick,
2004) and that regulation of cap-independent translation is
often used to respond to several cellular stresses in order to
allow immediate and selective changes in protein levels (Hol-
cik and Sonenberg, 2005). Along this line, cis-acting elements
have been also shown to respond to different cellular stresses
and to contribute in the promotion of translation initiation
through a cap-independent mechanism. This is the case of
N6-methyladenosine (m6A) residues whose levels in 50 UTRs
are increased upon different cellular stresses (Zhou et al.,
2015; Meyer et al., 2015). Notably, reanalysis of m6A cross-
linking and immunoprecipitation (CLIP) data (Zhao et al.,
2014) and m6A immunoprecipitation (IP) in myoblasts (Figures
S6P and S6Q) revealed that circ-ZNF609 is highly methylated,
suggesting a possible regulatory role of this modification in
circ-ZNF609 translational activity.
In conclusion, circ-ZNF609 provides relevant material to iden-
tify the factors required for the translation of this class of tran-
scripts devoid of cap and polyadenylated tails. Further work will
be required in order to understand whether circRNA translationresponds to specific stimuli or signals different from those regu-
lating protein synthesis conducted by linear mRNAs.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culture and treatments
Mouse myoblasts (C2C12, ATCC) were cultured in Growth Medium (GM, DMEM with 20% FBS, L-Glutamine 2 mM and Penicillin/
Streptomycin) and induced to differentiate in DM (FBS reduced to 0.5%). Human myoblasts (WT and DMD) were cultured in Growth
Medium (GM, DMEM with 10% FBS, L- Glutamine 2 mM, insulin 50 mg/ml, FGFb 25 ng/ml, EGGF 1 ng/ml, Penicillin/Streptomycin)
and induced to differentiate with Human Skeletal Muscle DM (Promocell).
Reverse transfection of human myoblasts with siRNAs was performed as follows: 96-well optical plates (Corning) were treated
overnight with 350 mg of Collagen Type I in water and 0.5% acetic acid, washed with PBS and UV-sterilized. Twenty microliters
of siRNA transfection mix (150 nM siRNA, 0.2 mL Dharmafect lipid reagent from Dharmacon, 20ml transfection medium: DMEM
with L-glutamine 2mM and insulin 50 mg /ml) was seeded in each well, left at RT for 20 min and then diluted with 30 mL of transfection
medium. Cells (12000 per well) were added after resuspension in double complete medium (GMwith 2X concentration of serum, an-
tibiotics, FGFb and EGF). Cells were switched to DM after 24h and fixed or collected for analysis at 48 hr and 96 hr.
HeLa and N2A cells were cultured in DMEM with 10% FBS, L-Glutamine 2 mM and Penicillin/Streptomycin 1X. HeLa and N2A
cells were transfected with 2 mg of plasmid DNA with Lipofectamine 2000. Two ml of lipofectamine were added to 300 mL of Opti-
mem with DNA, mixed and pipetted in a 35-mm plate with 200000 cells. Medium was replaced 4 hr later and cells harvested for
protein and RNA analyses after 48 hr. For heat shock experiments, p-circ3xF-tranfected HeLa cells were cultured at 44C for three
hours.e3 Molecular Cell 66, 22–37.e1–e9, April 6, 2017
METHOD DETAILS
RNA isolation, treatments and analysis
Total RNA in this study was extracted with Qiazol reagent according to the manufacturer’s protocol (QIAGEN). RNA from 96-well
plates and nuclear/cytoplasmic fractions was purified with miRNEasy spin columns according to the manufacturer’s specifications
(QIAGEN).
RNase R treatment was performed as follows: 1-10 mg of total RNA was diluted in 20 mL of water with 4u RNase R/mg unless differ-
ently stated and 2 mL of enzyme buffer (Epicenter), then incubated 15 min at 37C and purified by phenol chloroform extraction.
One pg of a DNA spike- in molecule was added to each reaction for qPCR normalization. DNA spike-in was produced from the mul-
tiple cloning site in pcDNA3.1(-) (Life technologies).
Retrotranscription of RNA in this study was performed with VILO Superscript (Life Technologies): up to 2 mg of RNAwere retrotran-
scribed in a 10 mL reaction mix with 1 mL of enzyme and 2 mL of buffer, incubated 10 min at 25C, 60 min at 42C and 5 min at 85C.
qRT-PCR analyses in this study were performed as follows: cDNA (2-10 ng equivalent) was added to a reaction composed of 7.5 mL
2X SYBRMastermix (QIAGEN), 1.5 mL of 5 mM primers and water to a final volume of 15 ml. DNA amplification (40 cycles of 95C for
30 s, 55C for 30 s and 72C for 30 s, followed by melting curve analysis) was monitored with an ABI 7500 Fast qPCR instrument.
RT-PCR for circRNA detection was performed with 0.2 mL of Mytaq DNA polymerase (Bioline) in 25 mL water with 5 mL reaction
buffer, 15 ng of cDNA, 2.5 mL 5mM primers. Reaction was carried out for 28 cycles at 95C for 25 s, 55C for 25 s, 72C for 25 s.
Five microliters of PCR were run on 2% agarose gels. All primers used in this study are reported in Table S2. RT-PCR for circular
and linear RNA from the same locus was carried out for the same number of cycles.
Northern blots
RNA (10-20 mg for detection of endogenous circRNA and 1-2 mg for detection of overexpressed circRNA) was denatured with one
volume of glyoxal loading dye (Ambion) for 30’ at 50C and loaded on 1.2% agarose gel. Electrophoresis was carried out for
2-3 hr at 60 V. RNA was transferred on Hybond N+ membrane (GE Healthcare) by capillarity overnight in 10X SSC. Transferred
RNA was cross-linked with UV at 12003 100 mJ/cm2 and the membrane was washed in 50 mM Tris pH 8.0 for 20 min at 45C. Pre-
hybridization and hybridization were performed in NorthernMax buffer (Ambion) at 68C (30min and overnight respectively). 500 ng of
DIG-labeled probe in 10 mL were used for hybridization. The membrane was then washed with 2X SSC 0.1%SDS twice 30min, then
once 30 min and once 1 hr with 0.2X SSC 0.1% SDS at hybridization temperature. The membrane was the processed for DIG detec-
tion (hybridization with anti-DIG antibody, washing and luminescence detection) with the DIG luminescence detection kit (Roche),
according to the manufacturer instructions. DIG-labeled probes were produced by in vitro transcription with DIG-RNA labeling
mix (Roche) of PCR templates produced with the oligonucleotides ZNF609_C_L_FW, ZNF609_C_L_T7_RV used with both human
and mouse cDNAs. Transcription with T7 RNA polymerase (Promega) was carried out overnight and the RNA was then loaded on
6% denaturing polyacrylamide gel, run for 1 hr in TB 1X at 100 V. The gel was stained with EtBr 1:10000 for 10 min, washed in
ddH2O for 10 min and the bands were cut and resuspended in 500 mL of Na Acetate 0.3 M, 0.1 mM EDTA, 0.2% SDS pH 5.5. Elution
was carried out overnight on a rotating wheel and the eluted RNA was purified by PCA and precipitated with 1 mL glycogen in 1 mL
100% Ethanol.
RNaseq and circular RNA detection
Illumina TruSeq library preparation was performed by Istituto di Genomica Applicata (Udine, Italy) from 1 mg of total RNA, depleted
of ribosomal RNA with Ribominus technology (Life Technologies). For each sample, 20-40 million 100bp long paired-end reads
were collected for each sample (GEO: GSE70389), then trimmed and analyzed as reported in QUANTIFICATION AND STATISTICAL
ANALYSIS, section ‘‘RNAseq analyses.’’
Cell fractionation
Nuclear/cytoplasmic fractionation of human and mouse cells was performed according to Legnini et al. (2014) as follows: cells
(1 3 106) were washed with PBS and immediately lysed on ice with 500 mL of cytoplasmic lysis buffer (140 mM NaCl, 1.5 mM
MgCl2, 10 mM Tris pH 7.5, 0.5% NP40) for 5 min. After scraping the cells and placing them in a 2 mL collection tube, 500 mL of a
sucrose cushion (same as lysis buffer with 12% Sucrose) was gently pipetted to the bottom of the tube. Sample was centrifuged
10 min at 12000 x g. Supernatant and pellet were then separately resuspended in 1 mL of Qiazol, while sucrose was discarded.
RNA extraction was carried out as described above.
Cytoplasm fractionations on sucrose gradients were performed as follows: 5x106 cells were lysed 5 min on ice with 500 mL of TNM
(10mMTris pH7.5, 10mMNaCl, 10mMMgCl2) lysis buffer supplementedwith 10mg/ml cycloheximide, 1XPIC (Complete, EDTA free,
Roche) and 1X RNase guard (Thermo Scientific), then spinned 2min at 15000 x g for discarding nuclear pellets. Samples were centri-
fuged on 9mL 15%–45%sucrose gradient at 38000 rpmwith a SW41 rotor (Beckman) for 1 hr 30min at 4C. Fractions were collected
with a Bio-logic LP (Biorad), 1 pg of a spike-in DNA as internal control was added to each fraction, together with 10 mg of glycogen,
100 mg of Proteinase K (Roche) and 40 mL of SDS. Samples were left 1 hr at 37C and RNAwas purified by PCA extraction and precip-
itated with isopropanol. DNA spike-in was produced amplifying the multiple cloning site from pcDNA3.1(-) (Life technologies).
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Western blots
Cells were harvestedwith 50-100 mL of Protein Extraction Buffer (100mMTris pH 7.5, EDTA 1mM, SDS 2%, PIC 1X (Complete, EDTA
free, Roche) and incubated 20min on ice, centrifuged at 15000 x g for 15min at 4C. Proteins (15-30 mg) were loaded on 4%–12%bis-
tris-acrylamide gel (Life technologies) and transferred to a nitrocellulose membrane. The membrane was blocked in 5%milk and hy-
bridized with the following antibodies, depending on the experiment.
FLAG protein sequence was detected by WB through F1804-1MG monoclonal anti-Flag M2 (Sigma-Aldrich).
Actinin andGAPDHwere detected byWB through polyclonal anti-Actinin (H-300) sc-15335 (Santa Cruz Biotechnology) andmono-
clonal anti-GAPDH (6C5) sc-32233 (Santa Cruz Biotechnology), respectively.
Immunofluorescence
Cells were washed twice in 100 mL PBS, fixed with 100 mL of 4% paraformaldehyde for 15 min at room temperature, washed twice
with 100 mL of PBS, permeabilized and blocked with 100 mL of PBS with 0.2% Triton X-100 and 1%goat serum, incubated with 50 mL
of in-house made anti-myogenin/anti-myosin antibody (available upon request), washed twice in PBS, incubated with 50 mL anti-
mouse Cy3/AlexaFluor488 secondary antibody diluted 1:300 in PBS-DAPI and finally washed twice in PBS. Acquisition for image-
based phenotypic analysis was performed with a widefield Nikon TiE Microscope equipped with a Lumencor SpectraX LED light
source and PerfectFocus 3; 4 3 and 10 3 objectives were used (Nikon Instruments). For image analysis see QUANTIFICATION
AND STATISTICAL ANALYSIS, section ‘‘Image Analysis.’’
For BrdU staining, we used 5-Bromo-20-deoxy-uridine Labeling and Detection kit I (Roche). Labeling reagent was added to the cell
culture medium (diluted 1:1000) 3 hr before fixation (human primary myoblasts) or 15’ before fixation (C2C12), then cells were fixed
with a solution made of 7 parts of ethanol and 3 parts of 50mM glycine at pH 2.0 for 20 min at –20C. Cells were then washed twice
with PBS and incubated for 1 hr at room temperature with 30 mL of antibody anti-BrdU diluted 1:10 in PBS. Cells were again washed
twice and incubated for 30 min with anti-mouse Cy3/AlexaFluor488 secondary antibody diluted 1:300 in PBS-DAPI and finally
washed twice in PBS. We took 4 pictures of each well with a Zeiss AXIO Observer A.1 with a 10X objective, both in the DAPI and
Cy3 channels. For BrdU image analysis see QUANTIFICATION AND STATISTICAL ANALYSIS, section ‘‘Image Analysis.’’
For immunofluorescence of p-lin3xF-transfected cells, they were fixed in 4% paraformaldehyde (Electron Microscopy Sciences,
Hatfield, PA) in PBS for 20 min at 4C. Cells were then washed in PBS and permeabilized and blocked with 0.2%Triton X-100
/0,2% BSA in PBS for 20 min at room temperature. Subsequently, cells were processed for immunostaining with anti-FLAG M2
primary antibody (Sigma Aldrich) diluted 1:1000 in 0,2% BSA/1% Goat Serum/PBS for 16h at 4C. Cells were then incubated with
secondary antibody (Goat anti-Mouse IgG Cy3-conjugated, Jackson ImmunoResearch, West Grove, PA) diluted 1:500 in 1%
Goat Serum/PBS for 45 min at room temperature. Finally, after extensive washing, DAPI (Sigma-Aldrich) was used to label nuclei
and the coverlips were mounted in ProLong Diamond reagent (ThermoFischer Scientific). Samples were imaged on an Olympus
IX73 invertedmicroscope equipped with Confocal Imager CREST X-LIGHT spinning disk, a CoolSNAPMyoCCD camera (Photomet-
rics) and a Lumencor Spectra X LED illumination. The images were acquired using a LUCPlanFLN 20X objective (NA 0,45) and a
UPLANSApo 60 X oil objective (NA 1.35) and collected with MetaMorph software (Molecular Devices). Stacks of images were taken
automatically with 0,2 microns between the Z-slices. All Z stacks were processed with ImageJ software and merged with maximum
intensity projection.
Protein IP and mass spec
Cells were trypsinized and pelleted at 500 g for 5 min, washed in PBS and lysed in an equal volume to the cell pellet of lysis buffer
(250 mMNaCl, 50 mM Tris pH 8, 5 mM EDTA, 0.8%NP40, 1 mMDTT, 5% glycerol, 50 mMNaF) with 20 strokes in a dounce homog-
enizer. Lysates were left on ice for 5 min and centrifuged at 15000 g for 10 min. Protein concentration of the supernatant was then
measured by Bradford assay and a volume containing 5-10 mg of proteins was diluted 1:2 in dilution buffer (50 mM Tris pH 8, 5%
glycerol). Fifty ml of protein G-coupled dynabeads (immunoprecipitation kit, Invitrogen) were washed in binding buffer (form the
kit), resuspended in 200 mL of binding buffer containing 10 mg of anti- FLAG M2 antibody (Sigma-Aldrich Aldrich) and left rotating
on a wheel for 1 hr at 4C. Beads were then washed in binding buffer and incubated with the diluted lysates in a final volume of
600-800 ml. The binding was carried out at 4C with the samples rotating on a wheel. Beads were then washed 3 times with low
salt wash buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1mM EDTA, 0.25% NP40, 5% glycerol), 2 times in high salt wash buffer
(same as low salt with 300 mM NaCl) and once in PBS. Samples were eluted with 20 ,l Elution buffer (from the kit) and 10 mL
LDS sample buffer (Invitrogen). Proteins were run on a 4%–12% polyacrylamide gel for 1 hr at 160 V and bands were cut according
to the protein marker between 30 and 40 KDa. Bands were stored at 4C in 300 mL H2O and sent for mass spectrometry analysis to
the proteomic platform at IGBMC - Strasbourg, where they were digestedwith trypsin and analyzed according to their standardmass
spectrometry pipeline.
m6A IP
Cells were washed twice with PBSand lysed with 2ml of Qiazol (QIAGEN). The RNA was extracted according to Qiazol protocol. The
m6A RIP was performed according to Dominissini et al. (2012) as follow: a volume containing 100 mg of RNA was diluted in a final
volume of 300 mL with IPP buffer (10 mM Tris pH 7.4,150 Mm NaCl, 0.1% NP-40) containing 10 mg of anti-m6A antibody and incu-
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The mixture was then immunoprecipitated by incubation with 50 mL of G-coupled dynabeads (immunoprecipitation kit, Invitrogen)
at 4C for an additional 2 hr.
Beads were then washed 5 times with IPP buffer and resuspended in 500 mL of Qiazol.
RNA was extracted according to Qiazol protocol and analyzed by qRT-PCR. Beads-only and isotypic IgG-coupled-beads were
used as negative controls.
Genome editing with Crispr/Cas9
The insertion of a 3xFLAG coding sequence at position 3 of the Zfp 609 exon 2, immediately before the stop codon, was obtained in
mouse embryonic stem cells by homology-directed repair of a Crispr/Cas9-induced DNA break. A guide RNA targeting the beginning
of Zfp 609 exon 2 was designed with CRISPR design (http://crispr.mit.edu) and cloned in a px330 vector (see Plasmid Construction
section). As a DNA donor, both a ssDNA oligo (ssDNA donor) and a plasmid donor carrying the same sequence plus 800 nt of ho-
mology upstream and downstream were used. Transfection of 500 ng of donor DNA plus 500 ng of px330 was performed in mES
cells with 2 mL of lipofectamine 2000. After 48 hr, cells were split and a half was used for gDNA extraction and genotyping. gDNA
was extracted with Real Genomics Genomic DNA extraction kit. Oligos crispr-A, B and C were used for amplifying the WT and re-
combinant alleles (Figure S6D) on control cells and transfected cells. PCR products were Sanger sequenced and the plasmid donor-
transfected cells resulted positive for the insertion. We diluted trypsinized cells at 0.5 cells/well in two 96 wells, and recovered a total
of 20 colonies with the plasmid donor-transfected cells. Colonies were split after 10 days and half of each was grouped producing
3 pools, which were separately genotyped. Pool #2 appeared positive, therefore the single colonies were further scrutinized and only
one positive clone was identified (named ‘‘F/D,’’ Figures S6E and S6F).
Plasmid construction
p-circ and p-circ-3xF were kindly provided by Hung Ho Xuan and Gunter Meister. Briefly, p-circ was produced by cloning the
circZNF609 sequence in the circRNA mini vector ZKSCAN1 (Kramer et al., 2015), addgene #60649) and p-circ-3xF was derived
by inserting a 3xFLAG-coding sequence (GACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGA
CGATGA CAAG) immediately upstream of the TAA codon present at position 3 in the circRNA sequence. We obtained the D1 deriv-
ative through inverse PCR on the p-circ-3XF vector with noATG1-ZNF609_FW and noATG1-ZNF609_RV oligonucleotides, while the
D2 with noATG2-ZNF609_FW and noATG2- ZNF609_RV, the p-STOP2 with STOP2_fw and noATG2-ZNF609_RV on the p-circ-3xF
template. The D1-2 was produced with an inverse PCR with noATG1-ZNF609_FW and noATG1- ZNF609_RV on the D2 template.
The p-lin-3xF vector was produced by inserting an amplicon obtained with pZNF_FW and pZNF_RV oligonucleotides from C2C12
gDNA using the In-Fusion HD Cloning Kit (Clontech) into pcDNA3.1- (Invitrogen), digested with EcoRI and NheI. The 3xFLAG tag was
then inserted into the resulting vector through inverse PCR with 3xFlag_1/2FW and 3xFlag_1/2RV oligonucleotides. The oligonucle-
otides (Flag_zfp_guide2_FW and Flag_zfp_guide2_RV) encoding the Cas9 guide RNA were annealed and ligated in a BbsI-digested
px330 vector (addgene #42230, (Cong et al., 2013)).
Luciferase bicistronic reporter constructs were obtained from pGL3-Control vector (Promega) and pRL-TK vector (Promega).
In order to get p-Luc empty vector, FLuc gene was isolated from pGL3-Control vector through the digestion with the restriction
enzymes NheI and XbaI. This fragment was ligated to pRL-TK Vector digested with NheI. ZNF609 50UTR was amplified with
FW_50UTR-circZNF609 and REV_50UTR-circZNF609 oligonucleotides and cloned between the two luciferase genes in p-Luc
empty vector, linearized by inverse PCR using FW_inversePCR-1 and RV_inversePCR-1 oligonucleotides. In order to obtain the
UTR vector, eighty-four nucleotides upstream the 50 splice junction of ZNF609 s exon were amplified with Fw_84ntZNF609 and
Rev_84ntZNF609-2oligonucleotides. The fragmentwas then inserted in the vector containing theZNF60950UTR, linearizedby inverse
PCR with FW_inversePCR-2 and RV_inversePCR-1 oligonucleotides. In order to get UTR+In.b Glob vector, eighty- four nucleotides
upstream the 50 splice junction of ZNF609 s exon were amplified with Fw_84ntZNF609 and Rev_84ntZNF609 oligonucleotides and
the second intron of Hbb-bs genewas amplifiedwith Fw_b-globin-intr2 and Rev_b-globin-intr2 oligonucleotides. The vector contain-
ing only ZNF609 50UTR was linearized as previously described, then the amplicons were cloned upstream ZNF609 50UTR to
obtain UTR+In.b Glob vector. ZNF609 UTR, 84-nucleotide fragment and Hbb-bs second intron were amplified from C2C12
gDNA by PCR. UTR+In.bGlob.D50ss vector was obtained by inverse PCR from UTR+In.bGlob vector, using Luc_DeltaSplicing_FW
and Luc_DeltaSplicing_RV oligonucleotides. In order to obtain UTR+In.-ZNF vector, 485 nucleotides from ZNF609 Intron 1-2 were
amplified frommouse gDNAwith FW_pLuc_In.Znf and RV_pLuc_In.Znf oligonucleotides. FW_pLuc_In.Znf contains forty nucleotides
from the 50 of ZNF609 Intron 2-3 right upstream the Intron 1-2 annealing sequence. This ampliconwas inserted into UTR vector, which
waspreviously linearizedby inversePCR,usingFW_inversePCR-2andRV_inversePCR-3oligonucleotides.UTR+In.HPRTvectorwas
obtained inserting HPRT Intron 8-9 into UTR vector, which was linearized by inverse PCR as previously described. HPRT Intron was
amplified frommousegDNA, usingFW_pLuc_In.HPRTandRV_pLuc_In.HPRToligonucleotides. In order to getMCS+In.bGlob vector,
p-Luc empty vector was linearized by inverse PCR, as previously described. The second intron of Hbb-bs gene was amplified from
UTR+In.bGlob vector, using FW_pLuc_In.bGlob_noUtr and RV_pLuc_In.bGlob_noUtr oligonucleotides. This amplicon was cloned
in p-Luc vector. Then, this construct was linearized by inverse PCR, using FW_inversePCR-1 andRV_inversePCR-4 oligonucleotides.
MCS sequence from pcDNA3.1(+) (Thermo Fisher Scientific) was amplified using FW_pLuc_MCS_noUtr and RV_pLuc_MCS_noUtr
oligonucleotides. This ampliconwas then cloned in the previous construct, in order to obtainMCS sequence downstream the bGlobin
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between luciferase genes (pLuc-EMCV-IRES) in p-Luc empty vector, linearized as previously described. UTR vector, UTR+In.bGlob
vector, UTR+In.-ZNF vector, UTR+In.HPRT vector, MCS+In.bGlob vector and EMCV-IRES vector were realized with In-Fusion HD
Cloning Kit (Clontech).
Preparation of synthetic circRNAs
The linear version of the flagged circZNF609 transcript was obtained by in vitro transcription from a PCR-generated template (using
p-circ-3xF as template and primers T7_ZNF_Flag_Fw and ZNF_Flag_Rv listed in Table S2) in presence of T7 polymerase (Promega)
following the manufacturer’s instructions. Upon DNase treatment, The RNA was purified through polyacrylamide gel electropho-
resis and the 50-terminal triphosphate removed by treatment with Alkaline Phosphatase (Roche) in presence of RNase inhibitors.
The RNA was then subjected to Ethanol precipitation upon the addition of 10 mg of glycogen (Roche). A phosphate group was
then attached to the 50-OH using ATP and T4 Polynucleotide kinase (BioLabs); the linear transcript carrying now 50-phosphate
and 30-OH ends was subjected to Ethanol precipitation in presence of 10 mg of glycogen (Roche). Ligase reaction was carried
out in a final volume of 100 ml, incubating the linear transcript at 95C for 2 min followed by 5 min at 75C in presence of 10%
DMSO and equimolar amount of splint DNA (oligo in Table S2). T4 RNA Ligase 1 (BioLabs), 1X T4 RNA Ligase Buffer, 10mM
ATP and RNase inhibitor will be then added and the reaction was carried out at 16C for 16 hr. The circularized RNA product
was separated and purified from the linear transcript by polyacrylamide gel electrophoresis. Thirty nanograms of both circular
and linear ZNF609 transcripts were subjected to RNase R treatment followed by qRT-PCR to assess the circularity of the gel-pu-
rified RNA molecules.
Luciferase assay
pLuc empty vector, pLuc-UTR vector, pLuc-intr.-UTR vector, pLuc-EMCV-IRES vector and pLuc-intr.-UTR-D-Spl. vector were
transfected in C2C12 cells as follows: 1 mL of lipofectamine 2000was added to 100 mL of Optimem together with 500 ng of DNA,mixed
and pipetted onto 50,000 pre-seeded cells in a 12 well plate. Medium was replaced 4 hr later and cells harvested for subsequent
analyses after 48 hr.
Cells were harvested with PLB lysis buffer (Promega) and RLuc and FLuc activities were measured by Dual Glo luciferase assay
(Promega) according to the manufacturer’s protocol. A part of cell lysate was kept for RNA extraction and checked by RT-PCR with
FLuc-pGL3control_FW and RLuc-pRLTK_RV oligonucleotides.
QUANTIFICATION AND STATISTICAL ANALYSIS
RNaseq analyses
For standard gene expression analysis, reads were mapped with TopHat, transcriptomes defined by Cufflinks and differential
expression analyzed with Cuffdiff. For circRNA detection, paired-end reads were split and used separately as input to the following
pipeline: reads were aligned to rRNA with Bowtie2, the remaining ones were mapped to hg19 or mm10 genome assemblies with
Bowtie2. Reads that were left after these alignments were used by FindCirc, Memczak et al., 2013) for finding circRNAs. For quan-
titative analyses of circRNA regulation in human muscle differentiation, circRNAs with at least 5 reads in one sample were used. The
total number of readsmapping to the head-to-tail splice junction was used formeasuring circRNA expression level, while themean of
total reads mapping linearly to the same splice junction was used for measuring the abundance of the linear isoform. For comparing
WT and DMD samples, circRNA expression level was normalized by dividing the reads mapping to the head-to-tail junctions by the
total number of spliced reads identified for each sample by FindCirc.
After the circRNA detection process, all human circRNA events were annotated using bedtools to the Ensembl GRCh37 gene
set. Annotation for gene structure features (CDS, UTR, Intron etc.) was performed with the R package CiRcus. For experimental
validation, a subset of circRNAs were selected according to the following criteria: human circRNAs were first filtered for expres-
sion (at least 5 unique reads in one sample, at least 2 unique reads in its biological replicate), then sorted by the average fold
change ratio between myotubes and myoblasts, then filtered for conservation (at least two unique reads in one sample in mouse
of an overlapping circRNA). The ones with an absolute fold change ratio > 2 were then sub-divided in 6 classes, according to the
expression pattern of their cognate mRNA: (circRNA upregulated > 2, downregulated < 0.5) x (mRNA upregulated > 2, downre-
gulated < 0.5, non regulated). Two or 3 of the top candidates were picked among each class, yelding a list of 16 circRNAs
(ACVR2A, ANKIB1, ASH1L, ASPH1, BNC2, DCBLD2, MEF2A, MYL4, NEB, PMS1, PTP4A2, RTN4, RUNX1, SEPT9, SLC8A1,
TMEFF1, TTN). Additional candidates were added according to their high expression level (HIPK3, ZNF292, BACH1, SPECC1,
RTN4bis) and their high circular/linear ratio (ADAMTS6, CAMSAP1, CDYL, MED13L, ZFHX3, ZNF609, TTTY16). To such list, we
added CRKL and QKI for the known role of their host genes in muscle differentiation. For each circRNA selection after sorting
for fold change, expression level, circular/linear ratio, we manually inspected the RNaseq coverage and isoforms expression,
and we manually excluded those situations that seemed too complicated for a validation experiment (too many isoforms, unex-
pected coverage, apparent trans-splicing events etc.). More details about bioinformatics analyses, all files and all scripts are avail-
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Image analysis
The acquired images were analyzed using two custom image analysis algorithms (available upon request), developed and executed
in the Acapella software development/run-time environment (Perkin Elmer). Both algorithms used a Perkin Elmer proprietary algo-
rithm on the DAPI staining for nuclei detection.
DAPI and MYOG staining at 48 hr were used to extract (for each siRNA treatment) the total cell number, the percentage of MYOG+
cells, and the average MYOG signal intensity. The DAPI&MYOG algorithm workflow can be summarized as follows: 1) nuclei detec-
tion (on DAPI channel); 2) MYOG signal intensity estimation (fromCy3 channel) and 3) MYOG ± nuclei classification. In the absence of
a cytoplasmic marker, following the segmentation on DAPI, Voronoi tessellations were used to define local regions for each detected
nucleus. Thus, foreground and backgroundmaskswere defined to represent the nuclear area and its local background. Thesemasks
were further used to extract average DAPI and MYOG intensities for every nucleus. The standard deviations of MYOG intensity in the
nuclei local backgroundwere estimated. TheDAPI/MYOG signal intensity of every nucleuswas defined as the difference between the
DAPI/MYOG intensities of its local foreground and background. This local approach compensates for both intra- and inter-image
spatial variability of illumination and minimizes possible errors in estimating DAPI/MYOG signal intensities over different wells
(and fields). Following a similar local approach, and this time compensating for different inter-image noise level/content, the
MYOG-positive and -negative classification was developed to use a local image adaptive threshold to apply on the MYOG signal
intensity. For each analyzed image, the threshold was defined as 1.5*median of all standard deviations of MYOG signal intensities
of the local backgrounds of all nuclei detected in the current image. Then, each nucleus was classified as MYOG+ or MYOG- based
on the comparison of its MYOG signal intensity and the current local image threshold (see the example Figure showing the MYOG-
positive classification).
DAPI and MHC staining at 96 hr were used to extract (for each siRNA treatment) the total number of cells, the percentage of MHC-
positive nuclei, and additional morphological parameters such as the fusion index and the number of nuclei per fiber. The algorithm
workflow can be summarized as follows: 1) nuclei detection (on DAPI channel); 2) nuclei count correction procedure; 3) cytoplasm
segmentation (on Red channel); 4)MHC signal intensity estimation (from theRed channel); 5) MHC-positive and -negative nuclei clas-
sification; 6) Red Cell/FiberMHC+ nuclei classification. Prior to all analyses, a circular mask was applied on the images of all channels
in order to remove vignetting.
Following DAPI segmentation of the nuclei, we applied a nuclei count correction procedure. This was required to overcome the
issue of contiguous, ‘syncytial-like’ nuclei that were present in myotubes. The nuclei count correction procedure was developed
based on a combination of some morphological features of the detected nuclei: the normalized nuclear area (with respect to the me-
dian of all nuclei area of the current image) and the nuclear axial length ratio (nucleuswidth/length). We could distinguish three classes
of nuclei. First, all nuclei having a normalized area smaller than 1, which count as 1 nucleus each. A second class was defined by
taking the integer of values derived after applying the floor function to nuclei with a normalized area greater than 1 (for example, nuclei
with values between 2.0 and 2.99were scored as 2, while those between 3.0 and 3.99 were scored as 3). Third, we defined a subclass
with all nuclei having a normalized area between 1.5 and 2 and with an axial length < 0.5 were counting as 2 nuclei each.
We used a Perkin Elmer proprietary algorithm to define the cytoplasmic area for each nucleus. The cytoplasmic area is assigned to
the nuclei based on the signal in the Red channel. This was associated with two problems. First, because of the peculiar morphology
of cells and fibers (cells have elongated shape, fibers appear stitched/clumpy and are multinucleated), individual cells/fibers were
erroneously subdivided. Second, in some cases, the method attempted to assign cytoplasm to cells that, on visual inspection,
had no signal in the Red channel.
Thus, we defined a population of ‘cell’ objects including a nuclear region (with one or more nuclei) and a cytoplasmic region. All the
detected ‘cell’ objects that had a cytoplasmic/nuclear area smaller than one were removed from the cytoplasmic segmentation
result, since they were potentially MHC-negative.
From the remaining population of cells, we defined a cellular mask (cytoplasm and nuclear areas) on which MHC-positive/negative
nuclei classification was performed. All nuclei with at least one quarter of their area overlapping the cellular mask were classified as
MHC-positive. All other nuclei were labeled as MHC-negative.
The Red Cell/Fiber classification was implemented using a work-around of the cytoplasm segmentation. The definition of a fiber
was as follows: stitched/clumpy cells with multiple and short distanced nuclei (clusters). Red Cells were defined as elongated and
mono-nucleate. We used the presence of nuclei clusters to differentiate between Red Cells and Fibers. Specifically, nuclei that
were within 100 mm of each other were defined as being part of the same cluster. Thus, we used the morphological dilation operator
(circular structuring element of 30 pixels diameter) on the nuclear mask given by all MHC-positive nuclei. The resulting ‘dilated’ mask
was then intersected (‘AND’ operator) with the cellular mask to separate nuclei of neighboring Red Cells. This resulting binary image
was used to define nuclei clusters by using connected component labeling (Ballard and Brown, 1982) and selecting only those com-
ponents containing more than one MHC-positive nucleus. Finally, all MHC-positive nuclei belonging to nuclei clusters were labeled
as ‘Fiber nuclei’. Similarly, all those MHC-positive nuclei that were not part of a nuclear cluster are labeled as Red Cell nuclei. The
result of this classification was transferred to the nuclei-associated ‘cell’ objects, and thus labeled as Fibers and Red Cells.
For each well, this algorithm reports a set of 8 parameters. The first four parameters are based on nuclei, namely, total number of
(detected) nuclei, percentage of MHC-positive nuclei, percentage of MHC-positive Red-Cell nuclei, average number of nuclei per
Fiber (estimated by the average number of nuclei per nuclei cluster). The following two parameters are cell area descriptors: the frac-
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to the entire area of the analyzed image. Two additional parameters were implemented to better describe cellular phenotypes. The
fusion index was defined as the fraction of total number of Fiber nuclei to the total number of detected nuclei. The maturation index
was defined as the fraction of the total number of Fiber nuclei to the total number of MHC-positive nuclei. All raw images, segmen-
tation results and scripts are available upon request.
BrdU images were analyzed manually by using ImageJ: tiff files were converted into binary images by setting a fixed threshold for
both DAPI and BrdU signal intensity, merged edged of close nuclei were split through the Watershed plug-in and nuclei count was
performed with the built-in particle analysis plug-in. Accepted nuclei dimension were set in a range corresponding to the second and
third quartiles of all particles detected.
Statistical Analyses
All experiments were repeated for at least 3 times unless differently stated in the legend; arithmetic means together with standard
error are reported in all plots shown in this study unless differently stated in the legend. Statistical significance for comparisons of
means was assessed by Student’s t test for qRT-PCRs, luciferase assays and immunofluorescence-based screenings. Dedicated
statistics were applied to RNaseq data analysis as specified in the legends. P values below 0.05 were marked by 1 asterisk, while
2 asterisks indicate a p value < 0.02 and 3 asterisks a p value < 0.01. When multiple comparisons were performed, p values were
scaled according to the Bonferroni correction and then filtered for corrected p value < 0.1.
DATA AND SOFTWARE AVAILABILITY
All software used in this manuscript is listed in the Key Resources Table. Additional dedicated scripts developed for this work are
available upon request. The accession number for the sequences reported in this paper is GEO: GSE70389.e9 Molecular Cell 66, 22–37.e1–e9, April 6, 2017
Molecular Cell, Volume 66Supplemental InformationCirc-ZNF609 Is a Circular RNA that Can Be
Translated and Functions in Myogenesis
Ivano Legnini, Gaia Di Timoteo, Francesca Rossi, Mariangela Morlando, Francesca
Briganti, Olga Sthandier, Alessandro Fatica, Tiziana Santini, Adrian Andronache, Mark
Wade, Pietro Laneve, Nikolaus Rajewsky, and Irene Bozzoni
 
 
Supplemental information 
 
Figure S1 
Human Genes
GM DM
FPKM>1 15004 15488
FPKM>10 6032 6009
FPKM>100 803 732
Diff. Expr. 3686 3303
FC>10 258 333
C2C12 (Mouse) Genes
GM DM
FPKM>1 12682 13019
FPKM>10 6244 6365
FPKM>100 907 879
Diff. Expr. 3848 3975
FC>10 359 404
Human C2C12 (Mouse)
FPKM
+1  GM
 B
FPKM
+1 DM
 B
FPKM+1 Repl. A
R2 = 
0.9989 
R2 = 
0.9869 
R2 = 
0.9977
R2 = 
0.9910
Human GO BP
C2C12 (Mouse) GO BP
C
2 C
12 (Mouse)
MHC CKM DMDMYOD
Hum
an
FPKM+1 Repl. A
FPKM+1 GMFPKM+1 GM
FPKM
+1 DM
A B
ig. S
C
D
GM DMGM DM GM DMGM DM GM DM GM DM GM DM GM DM
 
 
 
 
 
Figure S1. Related to Figure 1. RNAseq analysis of human and mouse myoblast differentiation.  
 (A) Number of genes expressed at various FPKM thresholds in human and mouse myoblasts (GM) and 
myotubes (DM), followed by number of genes differentially expressed according to Cuffdiff, and genes 
differentially expressed with a fold change >10. (B) Scatterplots showing correlation of RNAseq replicates 
(A and B) for human (left panels) and mouse (right panels) myoblasts (GM, upper panels) and myotubes 
(DM, middle panels); the correlation coefficient is shown on top left of each plot. Lower panels show 
FPKM of human and mouse genes in DM versus GM; genes differentially expressed according to Cuffdiff 
are highlighted in red. Fold change expression is indicated by 2 black lines at thresholds of 10 and 100. (C) 
Word clouds generated after gene ontology enrichment analysis of genes induced upon differentiation of 
myoblasts into myotubes (upper panel, human; lower panel, mouse). Non-differentially expressed genes 
were used as background. Word size is function of the enrichment of words found in gene ontology 
biological process. (D) qRT-PCR validation of myogenic markers in human (upper bar plots) and mouse 
(lower bar plots) myoblasts (GM) and myotubes (DM). FPKM values of the 4 markers MyoD (MYOD), 
Myosin Heavy Chain (MHC), Muscular Creatine Kinase (MCK) and Dystrophin (DMD), are shown in red. 
RNA levels measured by qRT-PCR, and normalized to HPRT, are shown in black. Bars show mean and 
standard error. 
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Figure S2. Related to Figure 2. Experimental validation and subcellular localization of selected 
circRNAs.  
 (A) RT-PCR validation of human circRNAs: circRNAs and the corresponding linear transcripts were 
amplified from cDNA obtained from myoblasts (GM) and myotubes (DM) in biological duplicates with 
divergent and convergent primers (see Table S2). Products were run on agarose gels together with RT-
minus controls. On the right side of the gels for circRNAs, black arrows indicate the circRNA amplicon 
and amplicons of the expected size derived by rolling-circle retrotranscription. (B) Same as in A for mouse 
samples. (C) Left panel: schematic representation of the possible concatemers generated by PCR after 
multiple rounds of retrotranscription. In red and blue the two parts of the PCR product generated by the 
indicated primers (arrows). Right panel: electropherograms showing the circular RNA-specific splice 
junction detected in RT-PCR products for human circ-CDYL, QKI and ZNF609. The splice junction is 
indicated by a black bar. Larger bands sequencing resulted in the pattern shown in the left panel. (D) 
Melting curve analysis post-qPCR for 6 selected circRNAs. (E) qRT-PCR validation of expression of 6 
selected circRNAs in human myoblasts (GM) and myotubes (DM) in biological duplicates (“A” and “B”). 
(F) RNA recovery after oligo dT purification of total RNA: barplots show the ratio of the RNA recovered 
in the unbound on the bound fraction for the circular (circ) and linear (lin) isoform of 6 candidates. qRT-
PCR data are normalized for a DNA spike-in. (G) RNA level after oligo dT and random examers (RE) 
retrotranscription: barplots show the ratio of the RNA amplified with RE on dT for the circular (circ) and 
linear (lin) isoform of 6 candidates. qRT-PCR data are normalized for a DNA spike-in. (H) RNase R 
validation of human circRNAs. circRNAs that were amplified by qRT-PCR from cDNA prepared from 
RNA treated or non-treated with RNase R, together with their corresponding linear RNAs. The ratio of 
treated versus non-treated, of circRNA versus corresponding linear RNAs, was tested by two tailed 
Student’s t test. Red bars: RNase R +; Blue bars: RNase R -. (I). Mouse samples were processed as in D. 
(J) Human circRNAs that passed the previous validation step were screened for subcellular localization by 
RT-PCR amplification from cDNA obtained by retrotranscribing nuclear and cytoplasmic RNA separately. 
Fractionation was performed in duplicate. (K) Mouse samples processed as in F. All bars show mean and 
standard error. 
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Figure S3. Related to Figure 3. CircRNA knock-down screening and validation.  
 (A) List of siRNAs designed to target human circular RNAs (NA – not applicable). (B) Knock-down 
efficiency of circRNAs and linear mRNAs for each siRNA, as measured in the high-throughput screening 
pilot experiment. All circRNAs/linear mRNAs level in control scramble siRNA (si-ctr) are set at 1. RNA 
levels in siRNA-treated cells are shown as fold change with respect to control and normalized to HPRT 
mRNA, measured by qRT-PCR. Levels of circRNA and linear mRNA are shown in red and blue, 
respectively. (C) A representative BrdU, Myogenin, Myosin and DAPI staining obtained in a pilot 
experiment in non-treated cells. (D) Knock-down of QKI and BNC2 circular and linear isoforms with the 
indicated siRNAs. Dark grey bars represent RNA level in negative control (si-CTR) and are set at 1. Light 
grey bars represent RNA level after siRNA treatment. All RNA levels are shown as mean and standard 
error and were measured by qRT-PCR in two independent experiments and normalized to Hprt mRNA. (E) 
Heat map showing selected “phenotypes” in color scale after Z-score normalization. High values are shown 
in blue, while low values in red. Each column indicates one phenotype, each row one sample, indicated on 
the right. The number of detected significant phenotypes is shown in red scale on the left.  
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Figure S4. Related to Figure 4. Circ-ZNF609 phenotype validation in mouse.  
 (A) RNA level of circ-ZFP609 and ZFP609 mRNA measured by qRT-PCR in C2C12 cells treated with si-
SCR and si-circ-ZFP609. (B) Percentage of the same cells positive for BrdU incorporation. Bars represent 
mean and standard error. 
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Figure S5.  Related to Figure 5. Circ-ZNF609 associates with polysomes.  
 (A) RNaseR treatment of total RNA with different amounts of enzyme. The percentage of the RNA, 
recovered after treatment and measured by qRT-PCR, is shown. (B) RNase R treatment of polysome-bound 
RNA (obtained by sucrose fractionation): the percentage of recovery of circular and linear ZNF609 in 
control and RNase R treated samples is shown. (C) RT-PCR performed on total RNA with primers 
designed on exons 1 and 3 of ZNF609. A black arrow indicates the expected size of the PCR product, while 
asterisks highlight the size of possible concatemers. (D) Fraction of circ-ZFP609 or HPRT mRNA (positive 
control) associated with heavy polysomes (HP), light polysomes (LP) and non-polysomes (NP) as 
measured by qRT-PCR after sucrose fractionation of C2C12 lysates without (CTR, dark grey bars) or with 
Puromycin treatment (PURO, light grey bars). The values are represented as mean and standard error of 
three independent fractionations.  
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Figure S6. Related to Figure 6. Translation of circ-ZNF609. 
 (A) Western blot analysis of proteins produced by p-circ-3xF and p-lin-3xF (serial dilutions) in HeLa (left) 
and N2A (right) cells. (B) Table showing the ratio between the protein produced by p-circ-3xF and p-lin-
3xF vectors (“C/L protein ratio”, measured by densitometric analysis on blots shown in the left panel), the 
ratio of the RNA produced by p-circ-3xF and p-lin-3xF measured by qRT-PCR with divergent and 
convergent primers (“C/L RNA ratio”, optimized for having amplicons of similar length in order to 
perform direct comparison), and the translation efficiency ratio obtained by dividing the amount of protein 
produced by the amount of RNA produced by the two vectors (“Norm. transl. eff.”). (C) 
Immunofluorescence of pcDNA and p-lin3xF-transfected HeLa cells with an αFLAG antibody. Left 
panels: αFLAG staining (red). Middle panels: αFLAG (red) and DAPI staining (blue). Right panels: 
αFLAG staining (red) of a 60X magnification of the area indicated by a dashed blue line in the 
corresponding left panels. (D) 1 µg of total RNA from HeLa (Human) and N2a (Mouse) cells transfected 
with the indicated constructs was analysed by Northern blot with a 32P-labelled probe against the circ-
ZNF609 sequence (α circ) and the precursor sequence (α lin). EtBr staining of the gels is shown aside. (E) 
Northern blot showing RNase R resistance of the circRNA produced by p-circ3xF in HeLa cells. (F) 
Schematic representation of the possible linear concatemers generated by trans-splicing between different 
molecules of primary transcript and primers used for their amplification. Such concatemers would contain a 
functional ORF giving rise to the proteins observed by p-circ-3xF overexpression. However, in addition to 
Northern blot (figure 6C), RT-PCR proves that such aberrant splicing products are not present. (G) RT-
PCR for concatemers. While rolling-circle RT-derived concatemers of circZNF609 are observed with 
divergent primers (left panel) even after 25 cycles of PCR, linear concatemers generated by trans-splicing 
in the cell are not observed with two distinct couples of primers after 25, 30 and even 35 cycles of PCR 
(middle and right panels). The expected size of such concatemers is indicated by asterisks. (H) Schematic 
representation of the ZNF609 locus and the plasmid donor used for Crispr/Cas9-mediated genome editing 
of mES cells. A 3xFLAG tag (in blue) is added to the endogenous circRNA sequence immediately before 
its stop codon (in red). Start codons are indicated in green. Primers for genotyping are indicated with 
arrows. (I) Genotyping of mES cells 48 hours after transfection with Crispr/Cas9 and donor DNA. Primers 
A and B amplify the WT locus, while A and C the recombinant locus, which is observed both in samples 
transfected with ssDNA and with plasmid DNA donors (left). Cells were then split and seeded at single cell 
density in 96 wells, and 34 clones where grouped in 5 pools, which were genotyped (right). (J) The clones 
from the two positive pools in (E) were genotyped separately: only one clone, named “F/D”, was positive 
for the 3xFLAG insertion in one allele. The second allele contained a deletion around the 3’ splice site 
(representative scheme on the bottom). Both alleles were characterized by Sanger sequencing. (K) Northern 
blot showing the presence of the tagged circRNA in “R/D” cells induced to neural differentiation. A probe 
recognizing both the circRNA and the mRNA was used (αC+L). EtBr staining of the gel is shown on the 
left. (L) Average of Phylo-P conservation score of the exons of the ZNF609 gene, divided by its 3 reading 
frames (in three grey shadows). (M) RT-PCR of the mature bicistronic mRNAs produced by the constructs 
shown in figure 6H, amplified by the primers FW and RV represented in the top panel. For the constructs 
carrying an intron, the two lines on the right indicate the expected sizes of the unspliced and spliced 
products. (N) Left panel: the polyacrylamide gel stained with EtBr shows the product of in vitro 
transcription before (- ligase) and after in vitro circularization obtained with T4 RNA ligase (+ ligase). The 
two bands where then eluted and tested for RNase R resistance (right panels). Bars represent mean and 
standard error of three technical replicates. (O) Top panel: Western blot analysis of HeLa cells transfected 
either with p-circ3xF (producing a FLAG-tagged circ-ZNF609 by back-splicing) or the synthetic FLAG-
tagged circ-ZNF609 from panel (K) (in-vitro circ, produced by in vitro transcription and ligation). 
Hybridization with an anti-FLAG antibody reveals protein production only from the plasmid. ACTN was 
used as loading control. Bottom panel: RT-PCR showing expression of the FLAG-tagged circRNA in HeLa 
cells transfected with either p-circ3xF or in vitro circ. Hprt mRNA is used as loading control. (P) In blue 
m6A CLIP sites identified in circ-ZNF609 sequence (top) in Zhao et al., 2014. (Q) qRT-PCR analysis of 
circ-ZNF609 after m6A immunoprecipitation in C2C12 myoblasts. Data are shown as % of input of RNA 
recovered after IP with anti-m6A antibodies (IP), isotypic IgGs (IgG) and beads only control (BO). 
 
 
 
 
Table S1: list of circRNAs detected by RNAseq (provided as a separate Excel file), related to Figure 1. 
Table S2: list of oligonucleotides used in this work (provided as a separate Excel file), related to STAR 
Methods. 
Table S3: list of siRNAs used in this work (provided as separate Excel file), related to Figure 3. 
 
 
 
